Evaluation and Management of Vaginitis.
Marnach ML, Wygant JN, Casey PM.
Mayo Clin Proc. 2022 Feb;97(2):347-358. doi: 10.1016/j.mayocp.2021.09.022.
Vulvovaginal candidiasis and vaginal microflora interaction: Microflora changes and probiotic therapy.
Sun Z, Ge X, Qiu B, Xiang Z, Jiang C, Wu J, Li Y.
Front Cell Infect Microbiol. 2023 Feb 3;13:1123026. doi: 10.3389/fcimb.2023.1123026. eCollection 2023.
Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review.
Kalia N, Singh J, Kaur M.
Ann Clin Microbiol Antimicrob. 2020 Jan 28;19(1):5. doi: 10.1186/s12941-020-0347-4.
A probiotic nanozyme hydrogel regulates vaginal microenvironment for Candida vaginitis therapy.
Wei G, Liu Q, Wang X, Zhou Z, Zhao X, Zhou W, Liu W, Zhang Y, Liu S, Zhu C, Wei H.
Sci Adv. 2023 May 19;9(20):eadg0949. doi: 10.1126/sciadv.adg0949. Epub 2023 May 17.
Vaginitis.
Banner EA.
Med Clin North Am. 1974 Jul;58(4):759-68. doi: 10.1016/s0025-7125(16)32119-8.
Diagnostic performance of DNA probe-based and PCR-based molecular vaginitis testing.
Navarathna DH, Lukey J, Coppin JD, Jinadatha C.
Microbiol Spectr. 2023 Oct 17;11(5):e0162823. doi: 10.1128/spectrum.01628-23. Epub 2023 Aug 24.
Enhancing Immunity and Modulating Vaginal Microflora Against Candidal Vaginitis Through Nanoemulsion Supplemented with Porphyra Oligosaccharide as an Intravaginal Vaccine Adjuvant.
Tsai WC, Liu FL, Huang MH, Huang CH.
Int J Nanomedicine. 2023 Nov 6;18:6333-6346. doi: 10.2147/IJN.S431009. eCollection 2023.
Candida vaginitis: virulence, host response and vaccine prospects.
De Bernardis F, Graziani S, Tirelli F, Antonopoulou S.
Med Mycol. 2018 Apr 1;56(suppl_1):26-31. doi: 10.1093/mmy/myx139.
Management of persistent vaginitis.
Nyirjesy P.
Obstet Gynecol. 2014 Dec;124(6):1135-1146. doi: 10.1097/AOG.0000000000000551.
Pathophysiology of vulvovaginal candidiasis.
Sobel JD.
J Reprod Med. 1989 Aug;34(8 Suppl):572-9; discussion 579-80.
